Primary:
To evaluate if progression-free survival from first treatment to progression or death during
second-line therapy (total PFS) of sorafenib followed by sunitinib is superior compared to
sunitinib followed by sorafenib.
Secondary:
1. Time from first treatment to progression during second-line therapy (total TTP)
2. Time to first-line treatment failure (progression, death, discontinuation due to
toxicity) descriptively in each arm
3. PFS in first-line and second-line treatment, descriptively
4. Overall survival, descriptively (data cut-off same as for primary endpoint)
5. Disease Control Rate (DCR); Response rates in first-line and in second-line (CR, PR, SD
according to RECIST criteria)
6. Cardiotoxicity analysis by means of echocardiography and NT-pro BNP with an interim
analysis after 100 patients of each arm have completed the study
7. Safety and tolerability